End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.99 CNY | +0.20% | -0.60% | -0.99% |
04-29 | Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-17 | Aodong Medicine's 2023 Profit Declines 18%; Revenue Up 20% | MT |
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach -100% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company appears to be poorly valued given its net asset value.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.99% | 2.48B | C | ||
+29.98% | 682B | C+ | ||
+31.74% | 586B | B | ||
-3.52% | 364B | C+ | ||
+18.59% | 327B | B- | ||
+4.07% | 285B | C+ | ||
+16.38% | 240B | B+ | ||
+9.49% | 209B | B- | ||
-8.75% | 203B | A+ | ||
+7.09% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000623 Stock
- Ratings Jilin Aodong Pharmaceutical Group Co., Ltd.